schizophrenia

News

Click claims FDA okay for first-in-class schizophrenia DTx

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

Patients

Two faced man's silhouette, one side blue, the other red, with faces in the background

In schizophrenia care, even the support system needs support

After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.

News

Newron charts course forward for stalled schizophrenia drug

Newron thinks it may have reached an agreement with the FDA on a way to get the US development of its schizophrenia candidate evenamide back on track.

News

CT-155, and Boehringer Ingelheim and Click Therapeutics logos

Boehringer transfers schizophrenia DTx selling rights to Cli...

Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.

News

NHS study will pick apart mental illness with data science

Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.

R&D

Representation of bipolar and other mental health disorders, Janus concept

The role of the opioid pathway in schizophrenia and bipolar ...

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.

Click claims FDA okay for first-in-class schizophrenia DTx

In schizophrenia care, even the support system needs support

Newron charts course forward for stalled schizophrenia drug

Boehringer transfers schizophrenia DTx selling rights to Cli...

NHS study will pick apart mental illness with data science

The role of the opioid pathway in schizophrenia and bipolar ...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

schizophrenia

Editor's Picks